Evolution Biotechnologies – Austin, Texas, May 20th 2021

Austin, Texas, May 20th 2021

Evolution Biotechnologies Inc., the Texas-based company extending the use of biological control into medically important areas, today announces the publication of an interview by Phage Directory (https://phage.directory/) in its online news source “Capsid and Tail”, under the title “Phages Before the Phrenzy: Part I — An interview with Dr. David Harper, CEO of Evolution Biotechnologies”.

The interview by Curtis Hoffmann is based on a discussions at the Phage Futures meeting in 2019, updated to reflect developments since that time.

The interview is available at: https://phage.directory/capsid/phages-before-the-phrenzy#article

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant infections in companion animals.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us

Evolution Biotechnologies – Austin, Texas, February 12th 2021

Austin, Texas, 12th February 2021

Evolution Biotechnologies Inc., the Texas-based company extending the use of biological control into medically important areas, today announces the publication of the book and web resource “Bacteriophages: Biology, Technology, Therapy”, published by Springer. Details are available on line at: https://www.springer.com/gp/book/9783319419855

Edited by three members of the Evolution team, along with Professor Steve Abedon of Ohio State University, Bacteriophages: Biology, Technology, Therapy is intended to cover all major, current aspects of work with bacteriophages. This ranges from basic biology to clinical trials of phage therapeutics and from early history to nanotechnology. In so doing, the book provides a single, readily citable source covering the biology of bacteriophages and bacteriophage infection, their use across a wide range of technologies, and their evolving use as therapeutic agents.

Dr. David Harper, CEO, said “This is an important work, providing a one-stop resource on all aspects of this important technology”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us

Evolution Biotechnologies – Austin, Texas, 13th September 2020

Austin, Texas, 13th September 2020

Evolution Biotechnologies Inc., the company extending the use of biological control into medically important areas, today announced the publication of two chapters on phage therapy written by its CEO, Dr. David R. Harper.

Entitled “Introduction to Bacteriophages” and “Intellectual Property Issues for Bacteriophages”, the chapters have been published on line by Springer Nature, prior to their inclusion in the book “Bacteriophages: Biology  –  Technology  –  Therapy” (http://www.springer.com/gb/book/9783319419855) to be published in early 2021.

Dr. Harper is the Editor-in-Chief of the book, working with Dr. Ben Burrowes, Dr. Malcolm McConville, and Professor Steve Abedon.

Dr. Harper said “This book will provide a key, wide-ranging resource for the sector as a whole, and we are all looking forward to its publication after years of work”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us

Evolution Biotechnologies – Austin, Texas, 30th August 2020

Austin, Texas, 30th August 2020

Evolution Biotechnologies Inc., the company extending the use of biological control into medically important areas, today announced the publication of a chapter on phage therapy written by its CEO, Dr. David R. Harper.

Entitled “Selection of Disease Targets for Phage Therapy”, the chapter has been published on line by Springer Nature, prior to its inclusion in the book “Bacteriophages: Biology  –  Technology  –  Therapy” (http://www.springer.com/gb/book/9783319419855) to be published in early 2021.

Dr. Harper is the Editor-in-Chief of the book, working with Dr. Ben Burrowes, Dr. Malcolm McConville, and Professor Steve Abedon.

Dr. Harper said “This book will provide a key, wide-ranging resource for the sector as a whole, and we are all looking forward to its publication after years of work”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us

Evolution Biotechnologies Austin, Texas, 15th August 2020

Austin, Texas, 15th August 2020

Evolution Biotechnologies Inc., the company extending the use of biological control into medically important areas, today announced the publication of a chapter on phage therapy written by its Senior Consultant, Dr. Ben Burrowes.

Entitled “Isolation of Bacteriophages”, the chapter has been published online by Springer Nature, prior to its inclusion in the book “Bacteriophages: Biology – Technology – Therapy” (http://www.springer.com/gb/book/9783319419855) to be published in early 2021.

Dr. Harper is the Editor-in-Chief of the book, working with Dr. Burrowes, Dr. Malcolm McConville, and Professor Steve Abedon.

Dr. Burrowes said “The book covers major aspects of phage biology and biotechnology that will be extremely useful for researchers and academics in the burgeoning field of phage biotech”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections, a key cause of both veterinary and human infections.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual “Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us
Website: www.evolutionbiotech.us

Evolution Biotechnologies announces expansion of operations in the United States

Austin, Texas, 17th January 2020

Evolution Biotechnologies the company extending the use of biological control into medically important areas, today announced the opening of Evolution Biotechnologies Inc., of Austin, Texas. The company is focussed on phage therapy, initially targeting the antibiotic resistant superbug Pseudomonas aeruginosa. This will initially target disease in companion animals as a basis for the later development of human therapeutics.

Further details can be found on the company website at www.evolutionbiotech.us.

Dr. David Harper, CEO, said “This is an important step forward for Evolution Biotechnologies, and for phage therapy as a whole, bringing the unique expertise resulting from our successful previous work to this important area, working to save and improve lives worldwide”.

About Evolution Biotechnologies

Evolution Biotechnologies Inc. (Registered USA No. 6050853) is working to bring phage therapy to market, using its unique, low-cost approach. The company’s initial target is antibiotic-resistant Pseudomonas aeruginosa infections in the canine ear. Once this has moved to commercial applications, company revenue will be used to support expansion into therapeutics intended for human use.

About phage therapy

Phage therapy is one of the most promising approaches to fighting antibiotic resistance. The basic approach has been around since 1919, but despite its long history and positive results from individual under ”Expanded Access” programs there has only been one successful modern clinical trial to demonstrate the efficacy of phage therapeutics. This was in a phase 1/2 clinical trial targeting drug-resistant Pseudomonas aeruginosa infections in both dog and human ear infections. These trials were managed by Evolution’s CEO, Dr. David Harper in a previous role. This unique experience underpins the work of Evolution Biotechnologies in moving phage therapy towards market.

Forward-looking statements

This document contains certain forward-looking statements – i.e., statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.us

Website: www.evolutionbiotech.us